Dare Bioscience, Inc. Common Stock — Quarterly Financial Statements (NASDAQ:DARE) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Market Capitalization 33.4869 M
Employee 24
Founded 2005
CEO Sabrina Martucci Johnson
Website www.darebioscience.com
Headquarter Delaware, United States
FIGI BBG001J2P362
Industry Biotechnology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

Price to earnings ratio

-1.61

Price to sales ratio

20.94

News

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates

Daré Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:DARE) 2026-03-26

Daré Bioscience extends NIH grant period for preterm birth drug

Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates

uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

Daré Bioscience gets FDA clearance for HPV treatment trial

Dare Bioscience launches preferred stock and warrant offering on Nasdaq

Dare Bioscience stock maintains Buy rating at H.C. Wainwright as Bayer exits

Daré Bioscience to regain rights to hormone-free contraceptive from Bayer

Daré Bioscience receives $3.6 million grant payment for contraceptive work

Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates